FTH

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.

The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth's technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company's PIKTOR clinical development progr.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment wit.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. “Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics,” said Anand Parikh, Chief Executive Officer. “.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance wit.